ABVC BioPharma, Inc. ABVC
At closeNov 6, 2026, 4:00 PM EST
After hours · Nov 6, 4:00 PM ET
- YTD
- -54.52%
- 1 year
- -65.89%
- Market cap
- 25.86M
- Revenue (ttm)
- 136.40K
- EPS (ttm)
- -0.30
- Shares out
- 12.24M
- Forward P/E
- -1.16
- YTD return
- -54.52%
- 1-year return
- -65.89%
- Volume
- 20.53K
- Avg volume
- 95.48K
- Open
- 0.96
- Previous close
- 0.9712
- Day's range
- 0.9501 – 0.98
- 52-week range
- 0.707 – 3.06
- Beta
- 0.82
5D -0.0412 (-4.08%)
Key statistics
- Enterprise value
- 8.67M
- PEG ratio
- 0.00
- Price / sales
- 45.78
- Price / book
- 0.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1817.50%
- Free cash flow
- -3.19M
- Total cash
- 199.98K
- Total debt
- 2.73M
- Return on equity
- -320.36%
- Short % of float
- 1.94%
- 50-day average
- 0.55548
- 200-day average
- 0.8008
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.02 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.09 | — | — |
| May 17, 2024 | Mar 1, 2024 | 0.00 | -0.40 | — | — |
| Mar 13, 2024 | Dec 1, 2023 | 0.00 | -0.35 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -0.82 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.68 | — | — |
About ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- abvcpharma.com
News
Your note
Sign in to keep a note on ABVC — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.55% | 71,607 | 36.52K | Sep 29, 2024 |
| Vanguard Group Inc | 0.36% | 46,947 | 23.94K | Sep 29, 2024 |
| Avantax Planning Partners, Inc. | 0.30% | 39,000 | 19.89K | Sep 29, 2024 |
| Xtx Topco Ltd | 0.18% | 23,405 | 11.94K | Sep 29, 2024 |
| Northern Trust Corporation | 0.15% | 19,135 | 9.76K | Sep 29, 2024 |
| State Street Corporation | 0.10% | 12,900 | 6.58K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.41% | 52,783 | 26.92K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.36% | 46,947 | 23.94K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.11% | 14,387 | 7.34K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 12,461 | 6.36K | Oct 30, 2024 |